PHARMACEUTICAL QUALITY MANAGEMENT
Investigate deviations and OOS/OOT, verify CAPA effectiveness, review batches and prepare inspection responses—with evidence, ownership and human review connected.
Interactive tour · Sample records · No customer data
The conclusion remains limited until the exact calibration record is verified.
A single case excerpt keeps the evidence gap, owner and next action readable.
Product tour · choose your workflow
Your selection stays active as you move through the tour and role views. Every example is read-only sample data.
LAB / OOS-017 · SAMPLE RECORD
Preserve the original result and testing rationale while comparing hypotheses against supporting and contradicting evidence.
CAPA / CAPA-011 · SAMPLE RECORD
Keep implementation evidence separate from effectiveness criteria, observation period and the reviewer’s outcome.
BATCH / B24091 · SAMPLE RECORD
See linked investigations, holds, document currency and downstream acknowledgement before disposition.
INSPECTION / INSP-009 · SAMPLE RECORD
Connect request ownership, due date, reviewed response, controlled sharing and historical reconstruction.
Product tour · selected workflow: Investigate OOS/OOT
The selected workflow stays in context while you inspect evidence, ownership, review gates and the Decision Passport. Sample data only; no customer records.
Inspect every step · sample records only. No approvals take place.
01 / 07 · Illustrative quality case
An excursion is reported with a controlled identifier, product context and initial owner. No conclusion is invented at intake.
02 / 07 · Illustrative quality case
Review the temperature log, batch record and relevant equipment history without hiding source versions.
03 / 07 · Illustrative quality case
The assistant can suggest a related record to inspect, but an investigator evaluates relevance and resolves evidence gaps.
04 / 07 · Illustrative quality case
The investigator documents which hypotheses are supported, what remains unresolved and why the proposed conclusion follows the evidence.
05 / 07 · Illustrative quality case
A corrective action has an owner, effectiveness criteria and an observation window. Completion alone does not prove the issue is resolved.
06 / 07 · Illustrative quality case
Role and workflow permissions govern review, decision meaning and signature. This public demonstration never signs a record.
07 / 07 · Illustrative quality case
A reconstruction connects what was raised, the sources examined, unresolved gaps, reviewer authority and the signed outcome when one exists.
Core pharmaceutical quality workflows
Each workflow exposes a practical outcome, a small evidence example and the accountable next action—without hiding the review boundary.
Build chronology, compare competing hypotheses and preserve supporting and contradicting evidence.
Separate implementation from effectiveness criteria, observation period, collected evidence and reviewed outcome.
Reconcile manufacturing and laboratory evidence with linked investigations, holds and document currency.
Review a reconciled batch population against a persisted source freeze, then track section review and follow-ups.
Connect SOP revisions to affected roles, retraining, competency evidence, expiry and effective authority.
Own requests and deadlines, review responses, control sharing and reconstruct what was known at the decision date.
Available according to tenant configuration, role permissions and intended use.
Current MES adapter scope is customer-specific: connection and qualification must demonstrate object-level and field-level reconciliation, corrections, duplicates and retries. Do not infer verified LIMS or ERP qualification from this example.
Same record · materially different work
The case identity stays consistent. The task, permitted action and responsibility change with the role.
My Work / Investigation
Priority: High · Due: Today · Blocker: calibration record.
Next action: verify the exact source before proposing a determination.
Mission Control + My Work / QA review
Priority: High · Due: Tomorrow · Blocker: unresolved calibration evidence.
Next action: confirm the rationale is supported before any authorized decision.
My Work / CAPA
Priority: Medium · Due: 19 Oct · Blocker: observation window incomplete.
Next action: attach implementation evidence and monitor the agreed effectiveness criterion.
Mission Control + My Work / Oversight
Priority: Portfolio view · Due: Mixed · Blocker: one source gap.
Next action: direct attention without overriding decision rights.
Navigation rule illustrated here: Quality Contributors lead with My Work; other authorized QMS manager/head roles can use Mission Control + My Work. Actual access remains tenant- and role-controlled.
Evidence → assistance → verification → decision
BayesPeaQ keeps AI assistance inside the evidence trail while accountable people retain review and decision authority.
TEMP-12 · Rev 02 is under review. CAL-PROBE-17 is still required, so the evidence set is incomplete.
Limitation: association does not establish causation; the investigator must verify source relevance.
The investigator resolves source relevance and contradictions. The QA reviewer evaluates the proposed determination, authority and remaining limitations.
Illustrative workflow only · not customer records, an electronic signature or qualification evidence.
For evaluators and validation leads
Use a focused walkthrough to review scope, intended use, your configuration and the evidence needed for a responsible deployment decision.
Show the records, investigation steps, approval roles and review gates relevant to your operation.
Discuss access roles, tenant configuration, integrations, data flow and records that remain external.
Request applicable testing, release and integrity evidence for your own validation assessment.
Request a workflow-specific walkthrough.We can review your workflow, relevant records, role handoffs, integration scope and qualification evidence.Selected workflow: Investigate OOS/OOT
A few useful answers
Pharmaceutical quality teams working across quality events, investigations, CAPA, change control and quality review. Workspace access depends on your organization’s assigned Quality role.
No. AI helps organize and compare evidence, surface context and identify gaps. Authorized people retain final quality decisions, signatures, release and closure authority.
Start with deviation investigation, evidence inspection, CAPA effectiveness and your authorized QA decision paths. Discuss additional scenarios such as APQR, batch disposition, recall readiness and management review according to your intended use and tenant configuration.
Yes—review applicable release, test, access-control and evidence-integrity materials for your own risk-based validation. Visit Trust & Validation for framework context; product features alone do not establish compliance.
Discuss source systems, record types, controlled import paths, organizational roles and configuration with the Bayes Pharma team before determining suitability.
Request a workflow-specific walkthrough →No. Use BayesPeaQ in your browser, or install the web app on a supported desktop or mobile browser for quicker access. Controlled quality records still require an authenticated connection.
Sign in with your platform account. BayesPeaQ checks your session and Quality role before opening the workspace. Contact your organization’s administrator if you need access.
Sign in to BayesPeaQQuality management built for evidence
Bring investigations, evidence, CAPA, approvals, quality decisions and inspection history into one governed system—then assess its suitability against your intended use and validation requirements.
Use in your browser or install for quick access.